Shah, NJ
Amit Shah, Wayne, NJ US
Patent application number | Description | Published |
---|---|---|
20090279479 | Wireless communication system and method of wireless communication - A wireless communication system is provided that includes a network and a plurality of access terminals. The plurality of access terminals includes a first group of access terminals configured to receive control information at a first data rate and send a response to the received control information, as well as a second group of access terminals configured to receive the control information at a second data rate and send a response to the received control information. The second data rate is higher than the first data rate. The network is configured to send the control information via a control channel at the first data rate and the second data rate, receive responses from the access terminals, and establish a traffic channel with at least one of the access terminals based on the control information and associated response from at least one of the access terminals. | 11-12-2009 |
Amit Shah, Piscataway, NJ US
Patent application number | Description | Published |
---|---|---|
20090199176 | SYSTEM AND METHOD TO SECURELY LOAD A MANAGEMENT CLIENT FROM A STUB CLIENT TO FACILITATE REMOTE DEVICE MANAGEMENT - Systems and methods are described for securely downloading management client software onto a device from an embedded stub in the device. In one embodiment, the stub client is activated by a message with credentials from a management server. The stub client, after verification of the credentials, downloads and activates a full management client. The management client then participates in any authorized management session with the device management server. The messages are preferably encrypted using a key that is based on the credentials. The credentials may be specific to the device and to the service provider associated with the device. | 08-06-2009 |
Anil Shah, East Windsor, NJ US
Patent application number | Description | Published |
---|---|---|
20100254923 | COMPOSITION AND PROCESS FOR PROTECTING CELLULAR TARGETS FROM AGING AND PHOTODAMAGE - The present invention is directed to a composition and process for protecting cellular targets from UV rays and free radical-induced damage by applying onto skin a composition containing: (a) at least one antioxidant chosen from 4-hydroxybenzylidene malonate derivatives and 4-hydroxycinnamate derivatives; (b) at least one extract of the plant | 10-07-2010 |
20110091401 | NOVEL WATER-RESISTANT SUNSCREEN COMPOSITION - The present invention is directed to sunscreen composition comprising: (a) at least one oil- and water repellent emulsifier chosen from polyperfluoroethoxymethoxy difluoroethyl PEG phosphate; (b) at least one hydrophobically-modified emulsifier chosen from inulin lauryl carbamate; (c) at least one gelling agent; and (d) sunscreen actives, and wherein the composition is water-resistant, while not requiring the use of a film-former, and is a stable emulsion. | 04-21-2011 |
20110189117 | COSMETIC COMPOSITION CONTAINING A POLYORGANISILOXANE POLYMER - The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising at least one polyorganosiloxane containing polymer comprising at least one moiety which comprises: at least one polyorganosiloxane group consisting of 1 to about 1000 organosiloxane units in the chain of the moiety or in the form of graft, and at least two groups capable of establishing hydrogen interactions. | 08-04-2011 |
20110300088 | WATER-INSOLUBLE REACTION PRODUCT OF A POLYAMINE AND AN OIL-SOLUBLE POLAR MODIFIED POLYMER - The invention relates to a water-insoluble reaction product of an oil-soluble polar modified polymer and a polyamine. | 12-08-2011 |
20120015016 | UV Protecting Composition And Methods Of Use - The present application relates to a UV protecting composition containing: (a) at least one organic UV sunscreen active; (b) at least one semi-crystalline polymer which is solid at ambient temperature and has a melting point of less than about 8O0 C; (c) hollow latex particles; and (d) at least one additional ingredient chosen from: i) a UV light absorbing compound having an SPF of less than 2, and ii) an SPF booster capable of reflecting UV light, different from hollow latex particles, wherein the hollow latex particles are employed in an amount equal to, or greater than, the amount of the at least one organic UV sunscreen active present in the composition. The invention also relates processes for protecting cellular targets from UV rays and free radical-induced damage by topically applying a UV protecting composition onto a keratinous substance, such as skin, and processes for making such compositions. | 01-19-2012 |
20130129649 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION FO UV FILTERS - The disclosure relates to sunscreen compositions having a synergistic combination of ultraviolet light (UV) filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high overall amounts of UV filtering agents. Furthermore, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation. | 05-23-2013 |
20130129650 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION OF UV FILTERS - The disclosure relates to sunscreen compositions having a synergistic combination of ultraviolet light (UV) filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high overall amounts of UV filtering agents, and without requiring the use of oxybenzone. Furthermore, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation. | 05-23-2013 |
20130142740 | SUNSCREEN COMPOSITIONS CONTAINING A NOVEL PRESERVATIVE SYSTEM - The present invention is directed to a sunscreen composition containing a novel preservative system for inhibiting micro-organisms comprising (a) at least one aromatic carboxylic acid, or salt thereof; (b) from about 0.01% to about 1% by weight of at least one at least one aromatic alcohol; (c) at least one sunscreen active; and (d) a cosmetically acceptable carrier. | 06-06-2013 |
20140170093 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION OF UV FILTERS - The disclosure relates to sunscreen compositions having a synergistic combination of ultraviolet light (UV) filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high overall amounts of UV filtering agents. Furthermore, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation. | 06-19-2014 |
20140170094 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION OF UV FILTERS - The disclosure relates to sunscreen compositions having a synergistic combination of ultraviolet light (UV) filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high overall amounts of UV filtering agents. Furthermore, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation. | 06-19-2014 |
20140170095 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION OF UV FILTERS - The disclosure relates to sunscreen compositions having a synergistic combination of ultraviolet light (UV) filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high overall amounts of UV filtering agents. Furthermore, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation. | 06-19-2014 |
20140170192 | SUNSCREEN COMPOSITIONS - The instant disclosure relates to sunscreen compositions. The sunscreen compositions include (a) at least one UV filter (b) at least one booster, (c) at least one thermosensitive polymer, and (d) at least one wetting agent. Sunscreen compositions comprising components (a)-(d) exhibit a surprisingly high sun protection factor (SPF). The disclosure further relates to methods of using the sunscreen compositions for protecting keratinous substances such as skin and hair from UV radiation. | 06-19-2014 |
20140186411 | LOW VISCOSITY META-STABLE PHOTOPROTECTION COMPOSITION - A meta-stable photoprotective composition, a product including the meta-stable composition, and a method of protecting a keratinous substrate from UV radiation by applying the product are provided. The meta-stable photoprotective composition includes at least one water-in-oil emulsifier having a hydrophilic-lipophilic balance (HLB) of less than 6, at least one non-ionic oil-in-water emulsifier having an HLB of greater than 9, at least one ionic surfactant, and at least one sunscreen active ingredient. The weight ratio of the at least one non-ionic oil-in-water emulsifier to the at least one water-in-oil emulsifier is about 0.2 to about 2.0. The meta-stable composition converts from an oil-in-water (O/W) emulsion to a water-in-oil (W/O) emulsion upon rubbing. | 07-03-2014 |
Asit Shah, Ridgewood, NJ US
Patent application number | Description | Published |
---|---|---|
20090319048 | Total Knee Replacement Prosthesis - A knee replacement prosthesis comprising a femoral component and a tibial component that enable anterior-posterior translation of the femur relative to the tibia and enable the tibia to rotate about its longitudinal axis during flexion of the knee. The femoral component connects to the distal end of a resected femur and includes medial and lateral condyles having distal, articulating surfaces, and a patellar flange having a patellar articulating surface. The tibial component connects to the proximal end of a resected tibia and includes a proximal bearing surface with medial and lateral concavities that articulate with the medial and lateral condyles. The articulating surfaces of the condyles and concavities are defined by sections of toroids. | 12-24-2009 |
20090319049 | Total Knee Replacement Prosthesis With High Order NURBS Surfaces - A knee replacement prosthesis comprising a femoral component and a tibial component that enable anterior-posterior translation of the femur relative to the tibia and enable the tibia to rotate about its longitudinal axis during flexion of the knee. The femoral component connects to the distal end of a resected femur and includes medial and lateral condyles having distal, articulating surfaces, and a patellar flange having a patellar articulating surface. The tibial component connects to the proximal end of a resected tibia and includes a proximal bearing surface with medial and lateral concavities that articulate with the medial and lateral condyles. The condylar articulating surfaces and the said concavities are substantially defined by non-uniform, rational B-spline surfaces (NURBS). | 12-24-2009 |
20100057088 | Distal Femoral Cutting Guide - An apparatus for resecting the distal face of either the left or right femur at a predetermined valgus angle relative to the patient's intramedullary canal prior to implanting the femoral component of a total knee prosthesis. The apparatus has a distal elongate sword having a longitudinal axis and being adapted for insertion into the intramedullary canal of the femur. A proximal handle is connected to and has a longitudinal axis coaxial with the sword. A base cartridge is fixed intermediate the sword and handle and has an axial passage extending therethrough. A face plate is fixed at the distal end of the base cartridge and is adapted to abut the face of the natural distal femur. The face plate is oriented at the predetermined valgus angle relative to the longitudinal axis of the sword. A cutting jig connects to the base cartridge. The cutting jig has a guide plate with at least one blade slot adapted to receive and guide a cutting blade, and a bracket that supports the guide plate and detachably engages the axial passage and orients the at least one blade slot at the predetermined valgus angle relative to the longitudinal axis. | 03-04-2010 |
20100292705 | Sizing Guide for Femoral Prosthesis - A posterior-referencing apparatus for sizing the resected distal femur prior to implanting the femoral component of a total knee prosthesis. The apparatus can be used for sizing either the left or right femur. The apparatus has a first operable orientation adapted for sizing the left femur and a second operable orientation offset 180 degrees from the first operable position for sizing the right femur. The apparatus can be reconfigured between left and right orientations quickly and easily without disassembling the apparatus. | 11-18-2010 |
20130123931 | Knee Revision Prosthesis With Progressive Restraint - A knee revision prosthesis that provides decreasing valgus-varus and medial-lateral restraint as the knee rotates from extension to flexion, and then increasing restraint as the knee rotates from flexion to full extension. The prosthesis includes a femoral component and a tibial component. The femoral component includes a guide box fixed to the femoral mounting surfaces intermediate the condyles. The tibial component includes a central post fixed intermediate the tibial concavities, which articulates within the guide box and constrains rotational movement of the femoral and tibial components relative to one another in the coronal plane and transverse planes. The post and guide box are constructed and arranged to provide progressively decreasing and then progressively increasing rotational constraint of the femoral component in the coronal and transverse planes as the femoral component rotates in the sagittal plane between full extension to a position in flexion, and then back to full flexion, respectively. | 05-16-2013 |
Birju Shah, Piscataway, NJ US
Patent application number | Description | Published |
---|---|---|
20120115962 | CYCLODEXTRIN-MODIFIED POLYAMINES FOR DELIVERY OF THERAPEUTIC MOLECULES - The present invention is directed to drug delivery vehicles comprising one or more cyclodextrin moieties conjugated to a dendritic polyamine for the delivery of small molecule and protein therapeutic molecules and nucleic acid therapeutic molecules, and methods of making and using the delivery vehicles. | 05-10-2012 |
Chetan Praful Shah, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20120132653 | Toothpaste Dispensing Regulator Cap - The present invention relates to a toothpaste dispensing regulator cap. The present invention comprises a lid member and a body member. The body member has an entrance orifice on one end that adapts to the neck of a toothpaste tube and an exit orifice on the other end that dispenses a “pea-size” amount of toothpaste into a thin layer along the bristle of the toothbrush. Additionally, the exit orifice has different shapes such as a star, box, or other designs so the stream of toothpaste that comes out will have a unique shape that appeals to a child and helps to develop good dental habits. | 05-31-2012 |
Chinmay Shah, Piscataway, NJ US
Patent application number | Description | Published |
---|---|---|
20090070597 | Method and Apparatus for Store and Replay Functions in a Digital Radio Broadcasting Receiver - A method includes: receiving a plurality of audio frames, assembling groups of the audio frames into logical recording units, storing a plurality of the logical recording units, retrieving the stored logical recording units, and decoding the retrieved logical recording units. An apparatus that performs the method is also provided. | 03-12-2009 |
20110274214 | METHOD AND APPARATUS FOR STORE AND REPLAY FUNCTIONS IN A DIGITAL RADIO BROADCASTING RECEIVER - A method for receiving and processing a digital radio broadcasting signal includes: receiving a digital radio broadcasting signal comprised of two or more multicast contents, playing a first one of the multicast contents, and concurrently storing a second one of the multicast contents. A receiver that implements the method is also provided. | 11-10-2011 |
20140056227 | METHOD AND APPARATUS FOR STORE AND REPLAY FUNCTIONS IN A DIGITAL RADIO BROADCASTING RECEIVER - A method for receiving and processing a digital radio broadcasting signal includes: receiving a digital radio broadcasting signal including encoded content in a first format; processing the encoded content to convert the encoded content into a second format; storing the encoded content in a second format; and decoding the stored encoded content to recover decoded content. A receiver that implements the method is also provided. | 02-27-2014 |
Chinmay M. Shah, Piscataway, NJ US
Patent application number | Description | Published |
---|---|---|
20090163137 | Systems and methods for communicating and rendering electronic program guide information via digital radio broadcast transmission - Methods and systems for preparing data for broadcast via digital radio broadcast transmission is disclosed comprising the steps of receiving a plurality of content files corresponding to programming information for program content to be broadcast; receiving an index file having a pointer for each of the plurality of content files, wherein the index file is associated with a first logical address; storing the index file and the plurality of content files; scheduling a broadcast rotation of the index file and the plurality of content files (wherein the index file is scheduled for repeated transmission intermittently relative to selected ones of the content files); and transmitting the index file and the plurality of content files to an importer in accordance with the broadcast rotation. | 06-25-2009 |
Fenil Shah, Edgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20100174789 | RESTFUL FEDERATION OF REAL-TIME COMMUNICATION SERVICES - A computer-implemented method that includes determining whether a predetermined collaboration client application is available locally at a local client, and using a proxy to integrate the collaboration client application into a web application of a web browser at the local client when the collaboration client application is unavailable locally at the local client, providing real-time presence awareness information of a plurality of users to a first user via the web application at the web browser, receiving, from the first user via the web application, a selection of at least one user of the plurality of users, with whom the first user desires to perform one or more real-time collaboration services, and determining at least one real-time collaboration service that is available via the web browser for use between the first user and the selected user, based at least in part on the real-time presence awareness information of the selected user. | 07-08-2010 |
20110320525 | SYSTEMS AND METHODS FOR ENABLING MOBILE MASHUPS - Methods and systems for enabling mobile mashups that amalgamate data and offerings from three dimensions: device features, Telecom network, and Web accessible services. Certain subject matter presented herein provides that this framework is established through middleware components, both on the server side as well as the device side, to provide support for mashing device and telecom interfaces. In addition, certain subject matter described herein provides for portability across different device platforms and different telecom operator networks. | 12-29-2011 |
Harsh Shah, Passaic, NJ US
Patent application number | Description | Published |
---|---|---|
20080251070 | Method and apparatus for capnography-guided intubation - A method and apparatus for qualitative sensory signal, capnography-guided intubation is provided. A qualitative sensory signal, such as an audible signal, is generated during intubation of a patient to provide an audible indication of carbon dioxide levels, so as to facilitate proper placement of an intubation tube. The frequency of the audible signal corresponds to measured carbon dioxide levels, thereby providing a simple, easy-to-interpret, audible indication of the current position of an endotracheal tube during intubation, as well as confirmation of proper placement of the tube. Alternatively, the qualitative sensor signal may be an omni-directional visual signal or a palpable vibratory signal. | 10-16-2008 |
Hemanshu S. Shah, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20080272022 | Variable-Dose Packaging System - The invention relates to a packages and kits for dispensing and/or administering pharmaceuticals, particularly for dispensing and/or administering combinations of different formulations. | 11-06-2008 |
20090030067 | Anti-proliferative combination therapy comprising satraplatin or jm118 and a taxane - The present invention describes a method of prevention and/or treatment of a cancer or a tumor, and in particular a combination therapy, methods, compositions and pharmaceutical packages comprising a taxane and certain platinum-based chemotherapeutic agents. | 01-29-2009 |
Jeckin Shah, North Bergen, NJ US
Patent application number | Description | Published |
---|---|---|
20110071418 | APPARATUS FOR DIAGNOSING MUSCULAR PAIN AND METHOD OF USING SAME - Apparatus and method for diagnosing a source of muscular pain, wherein the apparatus includes a housing, an electrical signal generator mounted within the housing, and a pair of electrodes, one of which is mounted on one end of the housing and the other of which is mounted on an opposite end of the housing. The generator may include either an analog waveform generator or a digital signal processor. Each of the electrodes stimulates a muscle with an electrical signal generated by the generator. One of the electrodes has a relatively small contact area for targeting smaller muscles or muscle groups, while the other electrode has a relatively large contact area for targeting larger muscles or muscle groups. The apparatus is a self-contained, wireless unit and is highly maneuverable, which allows a user to quickly and easily diagnose a source of muscle pain. | 03-24-2011 |
Kamlesh Shah, Monmouth Junction, NJ US
Patent application number | Description | Published |
---|---|---|
20090281304 | THERMALLY INHIBITED POLYSACCHARIDES AND PROCESS OF PREPARING - This invention is directed to a process for making a thermally inhibited polysaccharide by dehydrating a polysaccharide to substantially anhydrous or anhydrous conditions and thermally inhibiting the substantially anhydrous or anhydrous polysaccharide at a temperature of 100° C. or greater for a time sufficient to inhibit the polysaccharide in an oxygen enriched concentration of at least 6.5 moles/m | 11-12-2009 |
20130203983 | THERMALLY INHIBITED POLYSACCHARIDES AND PROCESS OF PREPARING - This invention is directed to a process for making a thermally inhibited polysaccharide by dehydrating a polysaccharide to substantially anhydrous or anhydrous conditions and thermally inhibiting the substantially anhydrous or anhydrous polysaccharide at a temperature of 100° C. or greater for a time sufficient to inhibit the polysaccharide in an oxygen enriched concentration of at least 6.5 moles/m | 08-08-2013 |
Kamlesh K. Shah, Monmouth Junction, NJ US
Patent application number | Description | Published |
---|---|---|
20130178615 | SINGLE-PHASE PREPARATION OF HYDROPHOBIC STARCH PRODUCT - A single phase preparation of free flowing, hydrophobic starches which comprises a starch treated with a siliconate and an acid in a single phase process, is described herein. | 07-11-2013 |
Kishore R. Shah, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20080220032 | ORAL CARE LAYER AND RELATED METHOD OF MANUFACTURE - An oral care composition including a hydrophilic, aliphatic, polyether-based thermoplastic polyurethane, a glycol polymer, and a poly(N-vinyl lactam). These components form a tacky film having a thickness of about 1 mils to about 50 mils. A whitening agent, such as a peroxide, can be absorbed into the tacky film, and adapted to desorb from the tacky film to whiten teeth to which the film is joined. A method is also provided in which the components are extruded through a twin screw extruder and output to a die to produce the film. The whitening agent can be deposited on the film and absorbed by the film to form a relatively stable oral care composition including the whitening agent. | 09-11-2008 |
20120157536 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF NON-STEROIDAL ANTI-FLAMMATORY DRUG - This invention pertains to compositions and method for transdermal administration of non-steroidal anti-inflammatory and analgesic drugs (NSAID) for the treatment of inflammation and pain caused by conditions such as arthritis, degenerative joint disease, minor strains, pains, and contusions. This invention particularly relates to transdermal compositions comprising an NSAID, a bioadhesive graft copolymer, and a skin penetration enhancer, selected from pyrrolidone or its derivatives and dialkyl sulfoxides and combinations thereof. | 06-21-2012 |
Mandar V. Shah, Rockaway, NJ US
Patent application number | Description | Published |
---|---|---|
20090239957 | STABILIZED GLYCEROPHOSPHATE-CONTAINING SURGICAL IRRIGATING SOLUTION - One aspect of the present invention relates to stabilized irrigating compositions comprising sodium glycerophosphate and/or calcium glycerophosphate, and a bicarbonate salt. Another aspect of the present invention relates to methods of irrigating ocular tissues during a surgical procedure comprising bathing the intraocular tissues with an irrigating composition comprising sodium glycerophosphate and/or calcium glycerophosphate, and a bicarbonate salt. | 09-24-2009 |
20090258955 | INTRAOCULAR IRRIGATING SOLUTION HAVING IMPROVED FLOW CHARACTERISTICS - Improved intraocular irrigating solutions are described comprising a cellulose derivative such as hydroxypropylmethylcellulose. In addition, certain solutions of the present invention comprise glutathione and dextrose. The solutions have enhanced viscosities that reduce the risk of damage to intraocular tissues during intraocular surgical procedures by reducing the turbulence of the solutions and dampening the movement of tissue fragments and air bubbles. The solutions preferably also have modified surface tensions that more closely resemble the surface tension of the aqueous humor. | 10-15-2009 |
20090264375 | INTRAOCULAR IRRIGATING SOLUTIONS AND METHODS FOR TREATING CORNEAL EDEMA - One aspect of the present invention relates to methods of treating corneal edema comprising contacting a cornea with an ophthalmic irrigating composition comprising histidine. In certain embodiments, the ophthalmic irrigating compositions contact the corneal endothelium. Another aspect of the present invention relates to ophthalmic irrigating compositions for treating corneal edema comprising histidine and optionally, calcium glycerophosphate and/or glutathione disulfide. | 10-22-2009 |
20100227003 | Self-Preserving Compositions - The invention provides self-preserving compositions and methods for their production. | 09-09-2010 |
20120213717 | Soothing Agents - In certain embodiments, the present invention is directed to the use of soothing agents to relieve mild irritation and/or enhance the overall soothing, comfort or refreshing feel of mucosal membranes of the eye, oral cavity, otic, nose, throat or vaginal area. The present invention further relates to compositions, articles and methods for masking or reducing the irritant properties of sensory compounds, such as terpenes and/or phenolic agents. | 08-23-2012 |
20140364401 | ANTISPASMODIC 1,2-DIOLS AND 1,2,3-TRIOLS - The present invention is directed to pharmaceutical compositions comprising antispasmodic C | 12-11-2014 |
Manish B. Shah, Somerset, NJ US
Patent application number | Description | Published |
---|---|---|
20090126721 | Continuous Fluid Bed Reactor - The present invention is concerned with an apparatus and method for continuous fluidization which comprises at least two cells connected by an aperture permitting the solid material to be introduced into the next downstream cell by fluidized horizontal flow, an isolated freeboard within each cell, at least two filter sticks contained within the isolated freeboard of each cell, and at least one blow back valve contained within each filter stick. The apparatus allows processing of materials that are typically difficult to fluidize by maintaining a substantially constant pressure difference between each isolated freeboard. | 05-21-2009 |
Manish J. Shah, West Caldwell, NJ US
Patent application number | Description | Published |
---|---|---|
20090253801 | Novel Antiarrhythmic Drug Formulations - The present invention provides a method of achieving a novel Propafenone formulation, which will have reduced number dosings and improved bioavailability. The present invention also applies to the salt and active metabolites of the parent and pro-drug. The novel compositions are designed to release Propafenone after oral intake in a manner, which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active is obtained. The time-specific pharmaceutical formulation, the disintegration of which is triggered by time lapse and the pH of the environment to which it is subjected. The novel compositions are also designed for administration once or twice daily. i.e. a therapeutically effective concentration of Propafenone is maintained for a period of at least 10-20 hours. A composition is designed to release Propafenone in at least the following consecutive steps: i) an initial relatively fast release of Prop afenone, ii) a second rise in release of Propafenone about 1-6 hours after oral intake; and iii) a third rise in release of Propafenone about 4-15 hours after oral intake, depending upon ones metabolism. | 10-08-2009 |
Manish S. Shah, Westcaldwell, NJ US
Manish S. Shah, West Caldwell, NJ US
Patent application number | Description | Published |
---|---|---|
20100291201 | COATED PHARMACEUTICAL CAPSULE DOSAGE FORM - Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient. | 11-18-2010 |
20110245967 | Secure Method for Delivering Regulated Items Including Drugs to a Patient - The present invention is generally directed to a method of dispensing regulated items, particularly drugs, directly to the patient via a dispensing system, without pharmacist intervention, that reduces human error associated with dispensing regulated items wherein a manufacturer or distributor of a regulated item establishes a dispensing system in communication with a data base wherein a prescriber is registered and enters patient data such as which regulated item is prescribed for the patient, characteristics such as sex, age, height, weight, etc., any other drugs the patient is currently taking or has a prescription for, any allergies to any particular drugs, substances, components, etc., reliable data for verifying the identity of the patient, and subsequently dispensing a regulated item directly to the patient from said dispensing system without pharmacist intervention, including communicating any necessary educational or instructional information to the patient concerning the regulated item and verifying the steps to the data base. | 10-06-2011 |
20120244216 | COATED PHARMACEUTICAL CAPSULE DOSAGE FORM - Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient. | 09-27-2012 |
20140248343 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE MORPHINE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 09-04-2014 |
20140248344 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE MORPHINE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 09-04-2014 |
20140271834 | Doxycycline Formulations, and Methods of Treating Rosacea - The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean C | 09-18-2014 |
20140271845 | COATED SUBSTRATE COMPOSITIONS - Pharmaceutical compositions in unit dose form comprising a hollow substrate and one or more coatings on the hollow substrate, wherein at least one coating comprises at least one active pharmaceutical ingredient, and methods of making the same are provided. | 09-18-2014 |
20140271898 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE - Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties. | 09-18-2014 |
20140275038 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE - Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties. | 09-18-2014 |
20140275039 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE - Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties. | 09-18-2014 |
20140275148 | ORALLY ADMINISTRABLE, SELF-SUPPORTING DISSOLVING FILM DOSAGE FORMS - Orally administrable, self-supporting, dissolving film dosage forms comprising an active ingredient and a polyvinyl alcohol-polyethylene glycol graft copolymer, and methods of orally administering the film dosage forms are provided. | 09-18-2014 |
20140275149 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE - Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties. | 09-18-2014 |
20140275150 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE - Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties. | 09-18-2014 |
20140377352 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE MORPHINE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 12-25-2014 |
20150017240 | PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT COMPONENT AND PH-RAISING AGENT - An oral pharmaceutical composition in unit dosage form comprising: (1) a first portion comprising: an active ingredient and a pH-dependent component, and (2) a second portion comprising a pH-raising agent is provided. Methods of administering the composition are also provided. | 01-15-2015 |
20150044282 | ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE OXYCODONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 02-12-2015 |
20150064245 | Abuse Resistant Forms of Immediate Release Hydromorphone, Method of Use and Method of Making - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-05-2015 |
20150064246 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE OXYMORPHONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-05-2015 |
20150064247 | ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE HYDROCODONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-05-2015 |
20150064248 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE HYDROMORPHONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-05-2015 |
20150071995 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE HYDROCODONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-12-2015 |
20150071998 | ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE OXYMORPHONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-12-2015 |
Matu J. Shah, Hackettstown, NJ US
Patent application number | Description | Published |
---|---|---|
20090018379 | Synthesis Of Chabazite Structure-Containing Molecular Sieves And Their Use In The Conversion Of Oxygenates To Olefins - In a method of synthesizing a silicoaluminophosphate or aluminophosphate molecular sieve comprising a CHA framework-type material, a synthesis mixture is provided comprising a source of aluminum, a source of phosphorus, optionally a source of silicon and at least one organic template of formula (I): | 01-15-2009 |
20090247802 | Synthesis Of Aluminophosphate And Metalloaluminophosphate Molecular Sieves - In a method of synthesizing an aluminophosphate or metalloaluminophosphate molecular sieve, a synthesis mixture is provided comprising water, a source of aluminum, a source of phosphorus, optionally a source of a metal other than aluminum, a tertiary amine, and an alkylating agent capable of reacting with said tertiary amine to form a quaternary ammonium compound capable of directing the synthesis of said molecular sieve. The synthesis mixture is maintained under conditions sufficient to cause the alkylating agent to react with the tertiary amine to produce the quaternary ammonium compound and to induce crystallization of the molecular sieve. | 10-01-2009 |
20090275789 | Treatment Of Small Pore Molecular Sieves And Their Use In The Conversion Of Oxygenates To Olefins - A method is disclosed of treating a porous crystalline molecular sieve having a pore size less than or equal to about 5 Angstroms to decrease its coke selectivity in oxygenate to olefin conversion reactions. The method comprises contacting the molecular sieve with an acid having a kinetic diameter greater than or equal to that of acetic acid. | 11-05-2009 |
20110112350 | Intergrown Molecular Sieve, Its Synthesis and Its Use in the Conversion of Oxygenates to Olefins - A molecular sieve comprises at least one intergrown phase of an AFX framework-type molecular sieve and a CHA framework-type molecular sieve and is conveniently synthesized using a combination of N,N,N′N′-tetramethylhexane-1,6-diamine and N,N-dimethylcyclohexylamine as organic directing agents. | 05-12-2011 |
20120157741 | Synthesis of Silicoaluminophosphate Having Lev Framework-Type - A process for producing a silicoaluminophosphate molecular sieve having the LEV framework-type employs at least one source of triethylmethylammonium, R | 06-21-2012 |
Mayur N. Shah, West Orange, NJ US
Patent application number | Description | Published |
---|---|---|
20100321243 | BACKGROUND POSITION FIX PRIOR TO REQUEST - A mobile station determines a usage pattern based on information stored from previous position fixes. The usage pattern is used to predict a time for a next position fix request. The mobile station performs a position fix in the background prior to the predicted time for the next position fix request. The background position fix provides the precise location and time of the mobile station to place the mobile station in a “hot” state. The prediction of the time for the next position fix request may be affected by the remaining battery power and/or the last known location of the mobile station. Additionally, the difference between the predicted time and the actual time of the next position fix request may be used to adjust subsequent predictions of the time for the next position fix request. | 12-23-2010 |
20110279317 | HIGH SENSITIVITY SATELLITE POSITIONING SYSTEM RECEIVER - An attenuated satellite positioning system (SPS) signal is acquired using long integration over multiple navigation data bits. To produce a stable internal clock signal to perform the long integration, an external clock signal is received from a highly stable source, such as a wireless communication base station or a nearby femtocell. An internal oscillator is driven at a desired frequency that is aligned with the scaled frequency of the external clock signal to produce the stable internal clock signal. The SPS signal is received and integrated for an extended period using the internal clock signal. Predicted SPS data may be received from an external source and used to perform coherent integration. Alternatively, non-coherent integration may be performed. Additionally, a motion sensor may be used to determine if there is motion relative to the external clock source or to compensate for Doppler errors in the external clock signal due to motion. | 11-17-2011 |
Mukund Shah, Hazlet, NJ US
Patent application number | Description | Published |
---|---|---|
20100280155 | Alkyltin Sulfanyl Mercaptocarboxylates Having Terminal Thiol Groups - An alkyltin compound of specified formula which has utility as an excellent stabilizer for a halogen-containing resin. The alkyltin compound has from 1-3 terminal thiol groups. | 11-04-2010 |
Navnit H. Shah, Clifton, NJ US
Patent application number | Description | Published |
---|---|---|
20100310659 | Compositions and Uses Thereof - Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane- | 12-09-2010 |
20120213827 | PROCESS FOR CONTROLLED CRYSTALLIZATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT FROM SUPERCOOLED LIQUID STATE BY HOT MELT EXTRUSION - A process for controlling the crystallization of certain hydrophobic active pharmaceutical ingredients (APIs) from a supercooled liquid state by hot-melt extrusion processing is described. Also described is a pharmaceutical composition comprising a solid crystalline dispersion of a cholesterol ester transfer protein inhibitor in a hydrophilic excipient matrix. In the process of the present invention, the API is fed to an extrusion system in a crystalline state contemporaneously with carrier excipients where it is first converted to a non-crystalline state by the application of heat and then subsequently recrystallized in-situ by the removal of heat and application of shear. Recrystallization of the API is controlled by carrier formulation design and the hot-melt extrusion process parameters; i.e. barrel temperature profile, feed rate, etc. | 08-23-2012 |
20140128431 | PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY, SAFETY AND TOLERABILITY - The invention relates to solid dispersions of poorly soluble compounds formed by coprecipitation, resulting in improved bioavailability, safety and tolerability. The invention also relates to Purified Eudragit L100-55 used to prepare such solid dispersions. | 05-08-2014 |
Navnit Hargovindas Shah, Clifton, NJ US
Patent application number | Description | Published |
---|---|---|
20080293787 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions. | 11-27-2008 |
20090054481 | Saquinavir Mesylate Oral Dosage Form - A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight. | 02-26-2009 |
20090281064 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS - The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone, and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof, which modified amino acid carrier is present in an amount effective to facilitate absorption of the bisphosphonate in the gastrointestinal tract such that the bisphosphonate is therapeutically effective. The ratio of bisphosphonate to modified amino acid carrier is from about 1:30 to about 1:1, respectively. These novel solid pharmaceutical dosage forms are useful in the treatment or control of bone diseases and particular disorders in calcium metabolism, including, for example, osteoporosis, hypercalcaemia of cancer, and the treatment of metastatic bone pain. The present invention also provides a method for treating these diseases employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms. | 11-12-2009 |
20100184716 | PHARMACEUTICAL COMPOSITIONS WITH SUPERIOR PRODUCT PERFORMANCE AND PATIENT COMPLIANCE - The present invention provides novel formulations of isobutyric acid (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-fluoro-2-isobutyryloxymethyl-4-methyl-tetrahydro-furan-3-yl ester) and hydroxypropylcellulose that provide high bulk density, low particle size better suited for improved compression and flow, good compression, and fast dissolution profiles. | 07-22-2010 |
20110027374 | CAPECITABINE RAPIDLY DISINTEGRATING TABLETS - There is provided a film coated pharmaceutical composition comprising 5′-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400μ), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Ludiflash® or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet. | 02-03-2011 |
20110028524 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions. | 02-03-2011 |
20110070303 | NOVEL DOSAGE FORMULATION - The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula I | 03-24-2011 |
20110245305 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions. | 10-06-2011 |
20120114751 | PHARMACEUTICAL COMPOSITION FOR TREATING HCV INFECTIONS - The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer. | 05-10-2012 |
20120129898 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions. | 05-24-2012 |
20130150382 | NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE - The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms. | 06-13-2013 |
20130172375 | PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition comprising a solid dispersion of a drug. In the composition, the drug is in substantially amorphous form. | 07-04-2013 |
20130189362 | NOVEL DOSAGE FORMULATION - The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula I | 07-25-2013 |
20130331314 | PHARMACEUTICAL COMPOSITION FOR TREATING HCV INFECTIONS - The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer. | 12-12-2013 |
20140206742 | PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY - The invention relates to solid dispersions of poorly water soluble compounds, in particular Compound A as disclosed herein, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds. | 07-24-2014 |
20150044287 | CAPECITABINE RAPIDLY DISINTEGRATING TABLETS - There is provided a film coated pharmaceutical composition comprising 5′-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400μ), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Pharmaburst C or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet. This tablet disintegrates in water at 37° C. in a USP Disintegration Apparatus in less than 2 minutes, preferably 1 minute and have a hardness of 8-13 strong Cobb-Units. | 02-12-2015 |
20150057296 | NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE - The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms. | 02-26-2015 |
Nilesh Shah, Monmouth, NJ US
Patent application number | Description | Published |
---|---|---|
20090262729 | SYSTEM FOR EFFECTING A TELEPHONE CALL OVER A COMPUTER NETWORK WITHOUT ALPHANUMERIC KEYPAD OPERATION - A system for effecting a telephone call between telephonic devices is operative to use a computer network, without manual use of the alphanumeric keypads. A third party call control (3PCC) application program interface (API) provides the capability for users to use a web browser or other Internet capable software to place a call, rather than using the telephone keypad. A third party call control application program interface includes a uniform resource locator operable over the Internet to cause a call between a first telephonic device and a second telephonic device to be completed. The uniform resource locator includes identification of the first telephonic device and identification of the second telephonic device. | 10-22-2009 |
20130089192 | SYSTEM FOR EFFECTING A TELEPHONE CALL OVER A COMPUTER NETWORK WITHOUT ALPHANUMERIC KEYPAD OPERATION - A system for effecting a telephone call between telephonic devices is operative to use a computer network, without manual use of the alphanumeric keypads. A third party call control (3PCC) application program interface (API) provides the capability for users to use a web browser or other Internet capable software to place a call, rather than using the telephone keypad. A third party call control application program interface includes a uniform resource locator operable over the Internet to cause a call between a first telephonic device and a second telephonic device to be completed. The uniform resource locator includes identification of the first telephonic device and identification of the second telephonic device. | 04-11-2013 |
Nimesh Shah, Marlton, NJ US
Patent application number | Description | Published |
---|---|---|
20080309491 | Comprehensive Theft Security System - An antitheft security system and method using networked pedestals for monitoring, and reporting data relating to, merchandise, having security tags coupled to or embedded therein, leaving or entering a business establishment and alerting business establishment personnel when a theft may be occurring. The system and method collect and communicate security tag data and associated peripheral device data to a remote server for analysis. | 12-18-2008 |
20120212343 | POINT OF ENTRY DEACTIVATION - A system and method for automatically deactivating a security tag upon entry into business establishment to prevent tag pollution. The system and method involve positioning a security tag deactivator at an entrance of a business establishment and emitting an EM field sufficient to deactivate any security tag that enters into the business establishment. | 08-23-2012 |
20140266728 | ELECTRONIC ARTICLE SURVEILLANCE PORTAL - A system and device for detecting and/or deactivating a security tag when passing through an electronic article surveillance (EAS) portal. The portal may be oriented by the arrangement of one or more antennas to generate an electromagnetic field at or within the portal to detect and/or deactivate the security tag. The electromagnetic field may detect and/or deactivate a security tag located at any orientation on merchandise as the security tag passes through the portal. The portal may be mounted on a counter at a point-of-sale station in which merchandise having security tags attached thereto are passed through the portal. The portal may also be mounted to a floor in which a shopping cart having merchandise is passed through the portal so that security tags attached to the merchandise in the cart are detected and/or deactivated. | 09-18-2014 |
Paresh C. Shah, Mt. Laurel, NJ US
Patent application number | Description | Published |
---|---|---|
20120030102 | FACILITATING A NETWORK COMMUNICATION SERVICE FOR A SUBSCRIBER LINKED TO A PLURALITY OF ACCOUNTS - There is provided a method that includes (a) receiving a notification of an event concerning a network communication service involving a subscriber, in which the subscriber is linked to a first account having first account terms, and a second account having second account terms, (b) making a decision of whether to handle the network communication service in accordance with the subscriber being linked to the first account or in accordance with the subscriber being linked to the second account, and (c) issuing a communication to a device to facilitate the network communication service, pursuant to the decision. There is also provided a system that performs the method, and a storage medium that contains instructions for controlling a processor to perform the method. | 02-02-2012 |
Pravin Shah, Rutherford, NJ US
Patent application number | Description | Published |
---|---|---|
20100098646 | Soap-Based Liquid Wash Formulations with Enhanced Deposition of Conditioning and/or Skin Appearance Enhancing Agents - The invention relates to soap-based liquid body and facial wash compositions. Using high solvent, low water compositions and incompletely naturalized fatty acids to help structure the compositions, all in combination with modified benefit agents, enhanced deposition of conditioning and/or skin appearance and/or optical enhancing agents is achieved. | 04-22-2010 |
20100098647 | Soap-Based Liquid Wash Formulations with Enhanced Deposition of Make-Up Agents - The invention relates to soap based liquid body and facial wash compositions. Using high solvent, low water compositions and incompletely neutralized fatty acid to help structure the compositions, all in combination with modified benefit agents, enhanced deposition of make-up agents is achieved. | 04-22-2010 |
20100098776 | SOAP-BASED LIQUID WASH FORMULATIONS WITH ENHANCED DEPOSITION OF ANTIMICROBIAL AGENTS - The invention relates to soap-based liquid body and facial wash compositions using high solvent, low water compositions and incompletely neutralized fatty acids to help structure the compositions, all in combination with modified benefit agents, enhanced deposition of antimicrobial agents is obtained. | 04-22-2010 |
20120039967 | Low Rub-Off Compositions - Low rub-off compositions comprising a silicon-based particle that encapsulates a colorant are described. The compositions can comprise a color generating component and are suitable to immediately impart an even color to skin when topically applied. | 02-16-2012 |
Priti Shah, Piscataway, NJ US
Patent application number | Description | Published |
---|---|---|
20090123398 | SILICON-FREE HYDROCARBONS PROVIDING AESTHETIC VOLATILITY - Non-silicone-based compositions including hydrocarbons of widely different structures and origins are combined into single, stable, homogenous products with both aesthetic and volatility properties similar to a cyclopentasiloxane. The combinations are useful to cosmetic formulators as full or partial replacement products for cyclopentasiloxanes, or “volatile silicones.” | 05-14-2009 |
20100143426 | COSMETIC DISPERSIONS UTILIZING A SILICONE-FREE HYDROCARBON COMPLEX - Silicone-free compositions including hydrocarbons of widely different structures and origins combined with coated particles are provided which have both aesthetic and volatility properties similar to cyclopentasiloxane dispersions. The compositions are useful as full or partial replacement products for dispersions of cyclopentasiloxane, or “volatile silicones.” The compositions are useful in UV-attenuating formulations including skin care products, color cosmetics, pharmaceutical products and especially sun care products such as sunblocks, sunscreens, tanning lotions, and the like. | 06-10-2010 |
Purvi Manoj Shah, Bridgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20120015841 | NOVEL CELL LINES AND METHODS - The invention relates to novel cells and cell lines, and methods for making and using them. | 01-19-2012 |
20140248639 | ASSAYS FOR IDENTIFYING COMPOUNDS THAT MODULATE BITTER TASTE - The present invention is based on applicants' discovery, disclosed herein, of agonists for the TAS2R receptors TAS2R1, TAS2R4, TAS2R9, TAS2R13, TAS2R14, TAS2R16, TAS2R44, TAS2R46, and TAS2R60. The assignment of agonists to these receptors makes assays for identifying compounds that modulate bitter taste possible. For example, the present invention provides methods of identifying compounds that inhibit the bitter taste due to these agonists. The present invention also provides methods of identifying compounds that selectively inhibit the bitter taste due to these agonists. The present invention further provides methods of identifying compounds that mimic the bitter taste due these agonists. The present invention also provides methods of identifying compounds that enhance the bitter taste due to these agonists. | 09-04-2014 |
Rajen Shah, Voorhees, NJ US
Patent application number | Description | Published |
---|---|---|
20110257239 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION AND METHOD OF RELEASING PHARMACEUTICALLY ACTIVE AGENT - The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amounts of a pharmaceutically active agent, hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected froth the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000. | 10-20-2011 |
Rajesh D. Shah, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20090095186 | Decoys for Infra-Red Radiation Seeking Missiles and Methods of Producing and Using the Same - The present invention relates to decoys for heat-seeking missiles and methods of producing and using the same. The decoys are designed to be kinematic or pseudo-kinematic, producing one or more infra-red radiation emitting clouds that give the appearance of a moving infra-red target in the airspace in which the decoy has been released. | 04-16-2009 |
20110283912 | Decoys for Infra-Red Radiation Seeking Missiles and Methods of Producing and Using the Same - The present invention relates to decoys for heat-seeking missiles and methods of producing and using the same. The decoys are designed to be kinematic or pseudo-kinematic, producing one or more infra-red radiation emitting clouds that give the appearance of a moving infra-red target in the airspace in which the decoy has been released. | 11-24-2011 |
20120097062 | USE OF PYROPHORIC PAYLOAD MATERIAL IN AMMUNITION TRAINING ROUNDS - The present invention relates to munitions employed for training and tactical purposes. Specifically, the present invention relates to training munitions (e.g., training rounds) used with various weapons (e.g., grenade launchers), wherein each training round includes a projectile that contains a pyrophoric payload that is released into the environment and reacts with air, upon impact of the projectile with an impact site. The reaction of the pyrophoric payload with air creates a signal that can be observed from a distance, thereby marking the landing or impact site of the projectile after it has been fired from a weapon. | 04-26-2012 |
20140208973 | DECOYS FOR INFRA-RED RADIATION SEEKING MISSILES AND METHODS OF PRODUCING AND USING THE SAME - The present invention relates to decoys for heat-seeking missiles and methods of producing and using the same. The decoys axe designed to be kinematic or pseudo-kinematic, producing one or more infra-red radiation emitting clouds that give the appearance of a moving infra-red target in the airspace in which the decoy has been released. | 07-31-2014 |
Ramesh M. Shah, Voorhess, NJ US
Patent application number | Description | Published |
---|---|---|
20120010279 | COMPOSITION COMPRISING (-)-DELTA9-TRANS-TETRAHYDROCANNABINOL - A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ | 01-12-2012 |
Samir Anupam Shah, Springfield, NJ US
Patent application number | Description | Published |
---|---|---|
20120022032 | CORTICOSTEROID COMPOSITIONS AND METHODS OF TREATMENTS THEREOF - This invention relates to steroidal solutions for the preparation of medicaments and drug products useful for treating diseases of the upper and lower airway passages. Various embodiments of the present invention provide compositions, compositions and dosage forms with mometasone furoate in a dissolved state that are suitable for inhalation and can be used for the treatment of diseases of the upper and/or lower airway passages. | 01-26-2012 |
Sangita Shah, Kendall Park, NJ US
Patent application number | Description | Published |
---|---|---|
20110258541 | METHOD AND APPARATUS FOR A TABBED MESSAGING INTERFACE - An approach is provided for improved messaging user interfaces. A subset of available messaging services is selected based, at least in part, on a touch control area of a user interface of a device. The user interface includes, at least in part, tabs corresponding to each of the available messaging services. Presentation of the user interface is caused, at least in part, at the device. The tabs presented in the user interface correspond to the subset. | 10-20-2011 |
20150046838 | METHOD AND APPARATUS FOR PROVIDING A MESSAGING INTERFACE - An approach is presented for interacting with a messaging user interface. A presentation is caused, at least in part, of a messaging user interface associated with one or more messaging services at a device. Presentation of a user interface element providing a link to one or more communications sessions corresponding to the messaging services is caused, at least in part. Selection of the user interface element causes, at least in part, presentation of representations of the communications sessions as one or more overlay elements on the user interface. | 02-12-2015 |
Sapna S. Shah, Jamesburg, NJ US
Patent application number | Description | Published |
---|---|---|
20100190759 | NK 1 ANTAGONISTS - A compound having the general structure shown in Formula I: | 07-29-2010 |
20120295879 | NK1 Antagonists - A compound having the general structure shown in Formula I: | 11-22-2012 |
20140296196 | NK1 ANTAGONISTS - A compound having the general structure shown in Formula I: | 10-02-2014 |
Saryu Shah, Watchung, NJ US
Patent application number | Description | Published |
---|---|---|
20110153381 | Method and System for Smart Queuing of Test Requests - A system and method for receiving a service ticket, determining a likelihood of success of re-testing the service ticket and performing additional steps, if the likelihood of success is greater than a predetermined re-testing threshold. The additional steps including determining a waiting time of the service ticket, adding the service ticket to a service ticket queue containing a plurality of service tickets, the service ticket queue being sorted by a waiting time of each of the plurality of service tickets, initiating performance of the service ticket, after an expiration of the waiting time, removing the ticket from the queue, if the performance of the service ticket is successful and re-start the waiting time, if the performance of the service ticket is unsuccessful. | 06-23-2011 |
Shailesh Shah, Livingston, NJ US
Patent application number | Description | Published |
---|---|---|
20090186086 | Solid multilayer oral dosage forms - Provided are multilayer compressed oral dosage forms comprising naproxen or a pharmaceutically acceptable salt thereof and sumatriptan or a pharmaceutically acceptable salt thereof. Processes of making and using the oral dosage forms also are described. | 07-23-2009 |
Shailesh A. Shah, Eatontown, NJ US
Patent application number | Description | Published |
---|---|---|
20110076225 | Hydrogen generator - A hydrogen generator capable of operating in any orientation and having no moving parts includes a catalyst retaining structure. The catalyst retaining structure is disposed in a housing and serves to separate the housing into a fuel holding portion and a hydrogen chamber. The catalyst retaining structure also includes one or more pores, each pore being in communication with the fuel holding and hydrogen chambers. A catalyst, that promotes the generation of hydrogen gas upon contact with the fuel, is disposed within the pores. The fuel enters the pores and thereupon generates hydrogen gas which passes into the hydrogen chamber. Contact of the fuel with the catalyst in the pores may be controlled and the position of the fuel-hydrogen interface within the pore may be moved so as to regulate the generation of hydrogen. The catalyst retaining structure can take different forms, including one or more hollow elongated members or plates, and may further incorporate hydrophobic and/or hydrophilic membranes. | 03-31-2011 |
Shrenik K. Shah, Metuchen, NJ US
Patent application number | Description | Published |
---|---|---|
20090258884 | Substituted amides - Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. | 10-15-2009 |
20100184758 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 07-22-2010 |
20100184799 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 07-22-2010 |
20120232039 | PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES - A compound having the structure | 09-13-2012 |
20120264777 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin sub-type receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 10-18-2012 |
20130289003 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES - A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. | 10-31-2013 |
20130296278 | Diazeniumdiolate Derivatives - A compound having the structure (I) useful for treating hypertension, pulmonary arterial hypertension, congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. | 11-07-2013 |
Shreya J. Shah, Lawrenceville, NJ US
Patent application number | Description | Published |
---|---|---|
20110044936 | Composition for Attracting Bed Bugs - The present invention provides a composition comprising an unsaturated aldehyde component and an organic acid component which is a powerful bed bug attractant when volatilized and released at very low concentrations. This attractant can be used to lure bed bugs to a location in which the bed bugs can be detected, monitored and/or trapped. | 02-24-2011 |
20110047860 | BED BUG CAPTURING DEVICE - The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element; and (b) a deadfall capturing element comprising at least one pathway comprising: (i) an upwardly sloped segment; (ii) a downwardly sloped segment having an outer portion; and (iii) a deadfall trap area: characterized in that the upwardly sloped segment and at least the outer portion of the downwardly sloped segment possesses an average surface roughness of at least about 2.5 micrometers. | 03-03-2011 |
20110072711 | AMPOULE FOR THE STORAGE AND DISPERSION OF VOLATILE LIQUIDS - In one aspect, the present invention is directed to an ampoule for the storage and dispersion of a volatile liquid comprised of (a) an outer shell composed of an impermeable material and defining at least one opening; (b) a porous diffusion member defining an internal reservoir positioned inside said outer shell; (c) a volatile liquid contained within such internal reservoir; and (d) a film member adhered to said outer shell and covering said at least one opening; wherein said film member is disposed such that an air space is present between said porous diffusion member and said film member; and wherein said porous diffusion member is configured such that molecules of the volatile liquid can only enter into said air space via diffusion through said porous diffusion member. Such ampoules are particularly suited for the storage and dispersion of organic chemicals useful as bed bug attractants, especially where such attractants are formulated in a highly volatile liquid, such as a C | 03-31-2011 |
20110072712 | BED BUG CAPTURING DEVICE - The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element comprising (i) a heavier than air organic chemical which attracts bed bugs; and (ii) a means for producing air flow such that the air movement from the device has a face velocity of between about 5 and about 50 ml/cm | 03-31-2011 |
Shreyas Shah, Dayton, NJ US
Patent application number | Description | Published |
---|---|---|
20120045512 | METHODS AND SUBSTRATES FOR DIFFERENTIATION OF NEURAL STEM CELLS - The present invention is directed to methods and substrates for promoting the differentiation of neural stem cells to neurons. | 02-23-2012 |
20120149781 | STEM CELL DIFFERENTIATION USING NOVEL LIGHT-RESPONSIVE HYDROGELS - This application discloses a light-responsive hydrogel-based platform that can modulate multiple microenvironmental signals to direct the differentiation of human induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) into neuronal cells. The invention provides novel methods for directing differentiation of neural stem cells into neurons useful for treatment of degenerative diseases or disorders, including but not limited to Alzheimer's, Parkinson's, or spinal cord injury (SCI). | 06-14-2012 |
20130236552 | NANOTOPOGRAPHY-MEDIATED REVERSE UPTAKE PLATFORM FOR NUCLEIC ACID DELIVERY AND APPLICATIONS THEREOF - This application discloses a nanotopography-mediated reverse uptake (NanoRU) platform useful for intracellular delivery of nucleic acids into mammalian cells, in particular stem cells, as well as methods of preparation and applications thereof. In particular, this system can be used to deliver small interfering ribonucleic acids (siRNAs) into neural stem cells and enhance neuronal differentiation of the stem cells. | 09-12-2013 |
20150081018 | METHODS AND SUBSTRATES FOR DIFFERENTIATION OF NEURAL STEM CELLS - The present invention is directed to methods and substrates for promoting the differentiation of neural stem cells to neurons. | 03-19-2015 |
Smita Shah, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20120095159 | Silicone Acrylic Hybrid Polymer-Based Adhesives - Silicone acrylic hybrid compositions prepared by reacting together silicone polymers, silicone resins, and silyl containing acrylic polymers are useful in adhesive compositions that find use in skin contact applications. | 04-19-2012 |
20140000807 | ACCELERATORS FOR TWO STEP ADHESIVE SYSTEMS | 01-02-2014 |
Syed M. Shah, East Hanover, NJ US
Patent application number | Description | Published |
---|---|---|
20090018208 | Novel Succinate Salt of O-Desmethyl-Venlafaxine - A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided. | 01-15-2009 |
20090137559 | BAZEDOXIFENE ASCORBATE - The present invention is directed to bazedoxifene ascorbate, compositions containing the same, dispersions thereof, preparations thereof, and uses thereof. | 05-28-2009 |
20100221445 | O-DESMETHYLVENLAFAXINE AND BAZEDOXIFENE COMBINATION PRODUCT AND USES THEREOF - A combination product containing at least two active compounds, O-desmethylvenlafaxine or a pharmaceutically acceptable salt thereof and bazedoxifene or a pharmaceutically acceptable salt thereof is described. Also described are methods of making and using this combination product to treat a variety of conditions associated with low circulating estrogen levels or low estrogen receptor activity. | 09-02-2010 |
20100249169 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF - The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids. | 09-30-2010 |
20100305323 | CRYSTAL FORMS OF (R)-N-METHYLNALTREXONE BROMIDE AND USES THEREOF - The present invention provides a new forms of (R)—N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist. | 12-02-2010 |
20110118216 | Tigecycline Compositions and Methods of Preparation - The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer. | 05-19-2011 |
20120059025 | DRY POWDER COMPOUND FORMULATIONS AND USES THEREOF - The present invention provides lyophilized formulations comprising methylnaltrexone, and processes for preparation of provided formulations. Additionally provided are compositions and products containing the methylnaltrexone formulation, as well as methods for producing formulations, compositions and products. Provided formulations as well as compositions and products containing methylnaltrexone formulations are useful for preventing, treating delaying, diminishing or reducing the severity and/or incidence of side effects resulting from administration of analgesic opioids. | 03-08-2012 |
Syed Muzafar Shah, East Hanover, NJ US
Patent application number | Description | Published |
---|---|---|
20090176720 | COMPOSITIONS CONTAINING PIPERACILLIN AND TAZOBACTAM USEFUL FOR INJECTION - An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution. | 07-09-2009 |
20100035845 | TIGECYCLINE FORMULATIONS - The invention is directed to a frozen pharmaceutical formulation suitable for administration to a subject parenterally, comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose, dextrose, glucose, mannose, sucrose, ribose, xylose and a combination thereof, wherein the formulation in a pre-frozen state at about 22° C. or in an unfrozen state at about 22° C. has a pH in the range of from 4.0 to 5.5. Preferably, the formulation is suitable for storage at or below about −20° C. over a period of at least about 2 months, preferably 6 months, more preferably 26 months. Alternatively, the formulation is suitable for storage at about 22° C. over a period of about 24 hours. | 02-11-2010 |
20110166091 | Compositions Containing Piperacillin and Tazobactam Useful for Injection - An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution. | 07-07-2011 |
20120277197 | TIGECYCLINE FORMULATIONS - The invention is directed to a frozen pharmaceutical formulation suitable for administration to a subject parenterally, comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose, dextrose, glucose, mannose, sucrose, ribose, xylose and a combination thereof, wherein the formulation in a pre-frozen state at about 22° C. or in an unfrozen state at about 22° C. has a pH in the range of from 4.0 to 5.5. Preferably, the formulation is suitable for storage at or below about −20° C. over a period of at least about 2 months, preferably 6 months, more preferably 26 months. Alternatively, the formulation is suitable for storage at about 22° C. over a period of about 24 hours. | 11-01-2012 |
20140004203 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA | 01-02-2014 |
Tanvi Rishin Shah, Jersey City, NJ US
Patent application number | Description | Published |
---|---|---|
20110231222 | Method and System for Enhanced Transaction Management - An integrated transaction module associated with an entity allows for consolidating and using information related to management of transactions. The integrated transaction system incorporates a transaction viewer for displaying information such as the companies involved in the transaction, level of interest shown by potential clients in hiring the entity to manage the transaction, whether or not the companies involved in the transaction present any conflict-of-interest for the transaction management company, and any attachments that may be relevant to the transaction. In addition, the integrated transaction system incorporates a transaction team conflicts checker to determine whether or not any of the team members involved in the transaction pose a conflict-of-interest and a best client analyzer for determining which of several potential clients offer the most benefits to the transaction management organization. | 09-22-2011 |
Tushar Shah, Jersey City, NJ US
Patent application number | Description | Published |
---|---|---|
20090281304 | THERMALLY INHIBITED POLYSACCHARIDES AND PROCESS OF PREPARING - This invention is directed to a process for making a thermally inhibited polysaccharide by dehydrating a polysaccharide to substantially anhydrous or anhydrous conditions and thermally inhibiting the substantially anhydrous or anhydrous polysaccharide at a temperature of 100° C. or greater for a time sufficient to inhibit the polysaccharide in an oxygen enriched concentration of at least 6.5 moles/m | 11-12-2009 |
20100261892 | THERMALLY INHIBITED POLYSACCHARIDES AND PROCESS OF PREPARING - This invention relates to thermally inhibited polysaccharides and improved processes of preparing them, wherein the improvement is dehydrating the polysaccharides under increased pressure and/or increased effective oxygen concentrations to produce compositions of improved organoleptic properties, including color, flavor and odor. | 10-14-2010 |
20120251659 | Use of Extruded Starch-Based Complexes for Satiety, Reduction of Food Intake, and Weight Management - The present invention relates to starch-hydrocolloid complexes, their preparation and their use in foods. The complexes positively impact the foods into which they are incorporated to give longer-lasting and/or more potent satiety, thereby helping energy management. The invention further relates to the reduction of food intake and/or management of weight by increasing such satiety. | 10-04-2012 |
20130203983 | THERMALLY INHIBITED POLYSACCHARIDES AND PROCESS OF PREPARING - This invention is directed to a process for making a thermally inhibited polysaccharide by dehydrating a polysaccharide to substantially anhydrous or anhydrous conditions and thermally inhibiting the substantially anhydrous or anhydrous polysaccharide at a temperature of 100° C. or greater for a time sufficient to inhibit the polysaccharide in an oxygen enriched concentration of at least 6.5 moles/m | 08-08-2013 |
20130289267 | THERMALLY INHIBITED POLYSACCHARIDES - This invention relates to thermally inhibited polysaccharides and improved processes of preparing them, wherein the improvement is dehydrating the polysaccharides under increased pressure and/or increased effective oxygen concentrations to produce compositions of improved organoleptic properties, including color, flavor and odor. | 10-31-2013 |
Tushar Kirit Shah, Edison, NJ US
Patent application number | Description | Published |
---|---|---|
20100185930 | METHOD AND APPARATUS FOR INCORPORATING APPLICATION FUNCTIONALITY INTO A WEB PAGE - A method and system incorporate server-side application functionality into client-side web pages. A web page includes a script tag that identifies a location on a server from which to acquire script code when a browser processes the script tag. An application running on the server receives a request for a data entry form when the browser executes script associated with the script tag. In response to this request, the application generates the data entry form, in one embodiment configuring attributes of the data entry form in accordance with user-supplied information. The application transmits the data entry form to the browser and maintains a state of user interaction with the data entry form. The application can subsequently capture and save user-supplied data submitted through the data entry form, and, based on the captured user-supplied data, state of user interaction, or both, determine a next screen presentation for the browser to render. | 07-22-2010 |
Unmesh Shah, Green Brook, NJ US
Patent application number | Description | Published |
---|---|---|
20090270432 | 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(- 1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5-AMINE - The compound having the structural formula I | 10-29-2009 |
20110059929 | SUBSTITUTED BICYCLIC PIPERIDINYL-AND PIPERAZINYL- SULFONAMIDES USEFUL TO INHIBIT 11beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 - In its many embodiments, the present invention relates to a novel class of substituted bicyclic piperidinyl- and piperazinylsulfonamide compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions. | 03-10-2011 |
20110135650 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS - The present invention provides a compound of Formula (I) | 06-09-2011 |
20110237559 | 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 - In its many embodiments, the present invention relates to a novel class of 6-substituted sulfonyl-1,3,3-trialkyl-6-azabicyclo[3.2.1]octane compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions. | 09-29-2011 |
20120040975 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Bridged Bicyclic Heterocycle Derivatives, compositions comprising a Bridged Bicyclic Heterocycle Derivative, and methods of using the Bridged Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient. | 02-16-2012 |
Unmesh G. Shah, Green Brook, NJ US
Patent application number | Description | Published |
---|---|---|
20100113487 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disease, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient. | 05-06-2010 |
20100190687 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of G protein-coupled receptor 119 (“GPR119”) in a patient. | 07-29-2010 |
20120021976 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS - The present invention relates to Bicyclic Piperidine and piperazine Derivatives, compositions comprising a Bicyclic Piperidine and piperazine Derivative, and methods of using the Bicyclic Piperidine and piperazine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient. | 01-26-2012 |
Uresh Shantilal Shah, Cranbury, NJ US
Patent application number | Description | Published |
---|---|---|
20100036123 | PROCESS FOR THE PREPARATION OF 2,4-DICHLORO-7H-PYRROLO[2,3H]QUINAZOLINE - The invention relates to a method of preparing 2,4-dichloro-7H-pyrrolo[2,3-h]quinazoline (II): | 02-11-2010 |
Vishal K. Shah, Plainsboro, NJ US
Patent application number | Description | Published |
---|---|---|
20090256561 | INTEGRATED MICROCHIP INCORPORATING ATOMIC MAGNETOMETER AND MICROFLUIDIC CHANNEL FOR NMR AND MRI - An integral microfluidic device includes an alkali vapor cell and microfluidic channel, which can be used to detect magnetism for nuclear magnetic resonance (NMR) and magnetic resonance imaging (MRI). Small magnetic fields in the vicinity of the vapor cell can be measured by optically polarizing and probing the spin precession in the small magnetic field. This can then be used to detect the magnetic field of in encoded analyte in the adjacent microfluidic channel. The magnetism in the microfluidic channel can be modulated by applying an appropriate series of radio or audio frequency pulses upstream from the microfluidic chip (the remote detection modality) to yield a sensitive means of detecting NMR and MRI. | 10-15-2009 |
Vishal T. Shah, Parlin, NJ US
Patent application number | Description | Published |
---|---|---|
20100072297 | Method for controlling hurricanes - A method for controlling hurricanes by raising temperature in the eye and/or in the outflow. Air temperature within the eye and in the outflow of a hurricane is raised by flying scores of jet planes with afterburners in the structure. Small changes in temperature on a large scale bring in large changes in other variables on the smaller scale to change the direction and intensity of the hurricane. | 03-25-2010 |